Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

4,500

Repayment of long-term debt (152,546) (183,969)

Proceeds from long-term debt 634,900 -

Repayment of repayable advances - (85,640)

------------ ------------

Cash provided by financing activities 456,220 14,282,840

------------ ------------

------------ ------------

Investing activities

Acquisition of property and equipment (544,844) (444,816)

------------ ------------

Cash used in investing activities (544,844) (444,816)

------------ ------------

------------ ------------

Increase (decrease) in cash and cash

equivalents (4,159,235) 12,477,478

Cash and cash equivalents - Beginning of

period 20,444,013 16,328,459

------------ ------------

------------ ------------

Cash and cash equivalents - End of period 16,284,778 28,805,937

------------ ------------

------------ ------------

Supplemental Information

Cash interest received 100,607 603,639

Cash interest paid 28,755 51,422

Non-cash transactions

Capital items included in accounts

payable 112,838 469,161

Share issue costs include
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PROVIDENCE, N.J. , Sept. 2, 2014   ... for MassBio,s 20th Annual Golf Classic, a major fundraiser ... event will be held on September 5 at the ... . The MassBioEd Foundation supports ... through educational programs, workforce development, and lifelong learning. ...
(Date:9/2/2014)... nanowires could be used for detailed studies of what ... important for pharmaceuticals research, among other applications. A group ... to make artificial cell membranes form across a large ... All communication between the interior of a cell and ... membrane is a surface layer that holds the cell ...
(Date:9/2/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... and Life Sciences: North America ... market for pharmaceutical, biopharma and life sciences is estimated at ... grow at a CAGR of 9.1% from 2014 to ... million in 2019. Browse the full Global ...
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2
... N.J., June 12 BioNeutral announced today the,results ... anthrax,spores on contact. This chemical technology is designed ... in conjunction with any suspected anthrax,exposure. "The Ygiene(TM) ... in as little as 15 seconds," said Dr. ...
... June 12 GenVault Corporation today,announces Paul J. ... Inc.,has joined its Board of Directors. Mr. Mirabella ... imaging with GE Healthcare where he held,leadership roles ... this substantial background in diagnostics and the healthcare,market, ...
... BRUNSWICK, N.J., June 12 Senesco,Technologies, Inc. ("Senesco" ... announced,that the Company will be presenting at the ... Annual International Convention,which is being held at the ... Galton, Chief Executive Officer of Senesco, will deliver ...
Cached Biology Technology:BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Senesco Technologies to Present at BIO 2008 Business Forum 2
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... A new study published in the September issue ... , identifies a novel strategy to diagnose the ... before irreversible structural damage has occurred. This advance ... diabetes on the endothelium of retinal vessels. Using ... to distinguish the early molecular development of diabetic ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... presents research on the genetic make-up and biology of ... better diagnosis and treatment of the diarrhea disease giardiasis, ... may also bring an understanding of several vital biological ... parasite that exists all over the world and causes ...
... GMES Programme approved the transition to Phase-2 of Segment ... of the programme by the ESA Council at ministerial ... 2 of 116%, giving a total amount of 500 ... ESA to confirm the development of the first three ...
... Now Fully Supports M2SYS Fingerprint Technology to ... Accurately Verify Check Casher Identity, ... biometric,technology research and development firm, announced today its partnership,with ... solutions, to integrate the M2SYS Bio-Plugin(TM) fingerprint,solution into TeraCash, ...
Cached Biology News:New Swedish research hope for millions of sufferers 2M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security Within Check Cashing Solution 2
... is a simple, easy to use ... bacterial and yeast applications. The ... voltages and either one mm, two ... pressing the pulse button the electroporator ...
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
MOUSE ANTI GTP BINDING PROTEIN...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: